Seladelpar FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 10, 2024.
FDA Approved: No
Generic name: seladelpar
Company: CymaBay Therapeutics, Inc.
Treatment for: Primary Biliary Cholangitis
Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist in development for the treatment of primary biliary cholangitis.
- Primary biliary cholangitis (PBC) is a rare, chronic inflammatory liver disease characterized by cholestasis and the accumulation of toxic bile acids in the liver, leading to inflammation and destruction of the bile ducts. Symptoms include pruritus and fatigue, which can be debilitating. Progression of PBC is associated with an increased risk of liver-related mortality.
- Seladelpar is a PPARδ agonist that works in the treatment of PBC by regulating critical metabolic and liver disease pathways involved in bile acid synthesis, inflammation, fibrosis and lipid metabolism, storage, and transport.
Development timeline for seladelpar
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
